Beacon Therapeutics

Beacon Therapeutics is dedicated to saving and restoring the vision of patients through innovative ophthalmic gene therapy. Founded in 2023, Beacon Therapeutics is focused on addressing a range of prevalent and rare retinal diseases that can lead to blindness. With a strong scientific foundation, Beacon Therapeutics is advancing a late-stage development candidate for X-linked retinitis pigmentosa (XLRP), along with two preclinical programs targeting dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD).

Beacon Therapeutics' lead development candidate, AGTC-501, is currently in Phase II clinical trials for the treatment of XLRP, an inherited disorder causing progressive vision loss. AGTC-501 expresses the full-length RPGR protein, addressing photoreceptor damage caused by XLRP. Additionally, Beacon Therapeutics utilizes a target generation technology platform to identify and screen secreted proteins in the ophthalmology field. Beacon Therapeutics is located at 14193 NW 119th Terrace, Suite #10, Alachua, Florida 32615, US; 188 York Way, Rolling Stock Yard, 2nd floor, London, N7 9AS, GB; and One Kendall Square, 1400W, suite 14102, Cambridge, MA 02139, US.

Beacon Therapeutics is committed to making a significant impact in the field of ophthalmology through its research and development efforts. Supported by Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences, and other investors, Beacon Therapeutics is well-positioned to advance its pipeline and bring innovative treatments to patients in need. We invite the management team at Beacon Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.